Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Acelyrin Inc
(NQ:
SLRN
)
4.790
+0.250 (+5.51%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,055,761
Open
4.610
Bid (Size)
4.600 (1)
Ask (Size)
4.900 (1)
Prev. Close
4.540
Today's Range
4.520 - 4.960
52wk Range
3.360 - 29.33
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
ACELYRIN, INC. to Participate in Upcoming Investor Conferences
August 22, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
Fabrinet Posts Strong Earnings, Joins Amer Sports, Hawaiian Holdings And Other Big Stocks Moving Higher On Tuesday
August 20, 2024
Via
Benzinga
Performance
YTD
-39.67%
-39.67%
1 Month
-28.83%
-28.83%
3 Month
+18.27%
+18.27%
6 Month
-41.30%
-41.30%
1 Year
-80.46%
-80.46%
More News
Read More
Acelyrin Cuts Workforce, Deprioritizes Former Lead Drug Izokibep
August 14, 2024
Via
Benzinga
Ouster Reports Weak Sales, Joins Brinker International And Other Big Stocks Moving Lower In Wednesday Pre-Market Session
August 14, 2024
Via
Benzinga
SLRN Stock Earnings: Acelyrin Misses EPS for Q2 2024
August 13, 2024
Via
InvestorPlace
SLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024
May 15, 2024
Via
InvestorPlace
SLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023
March 28, 2024
Via
InvestorPlace
ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results
August 13, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024
August 06, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
July 08, 2024
Via
Benzinga
ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024
June 05, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024
May 29, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN ALERT: Bragar Eagel & Squire, P.C. is Investigating Acelyrin, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
May 17, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
May 09, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN, INC. Announces Leadership Transition
May 09, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
April 29, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
March 28, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
March 27, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Investors Cheer Acelyrin's Stock, Its Second Lead Candidate Shows Clinical Benefit In Thyroid Eye Disease Patients
March 20, 2024
Via
Benzinga
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease
March 20, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
Acelyrin's Lead Drug Candidate Hits Primary Goal In Late-Stage Psoriatic Arthritis Study
March 11, 2024
Via
Benzinga
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
March 11, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients
March 11, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications
February 15, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
Acelyrin (SLRN) Investor Update: Kaplan Fox & Kilsheimer LLP Reminds Acelyrin Investors of a Class Action Lawsuit and Upcoming Deadline
January 16, 2024
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.